2-(2,6-dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide | 667906-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2,6-dichloro-phenylamino)-4-trifluoromethyl-pyrimidine-5-carboxylic acid benzylamide
• 英文别名: N-benzyl-2-(2,6-dichloroanilino)-4-(trifluoromethyl)pyrimidine-5-carboxamide
• CAS: 667906-33-4
• 化学式: C₁₉H₁₃Cl₂F₃N₄O
• 分子量: 441.24
• InChiKey: JJIAHHAJAFHVSM-UHFFFAOYSA-N

物化性质

• 密度：
  1.468±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Pyrimidine compounds
  申请人：Eatherton John Andrew

  公开号：US20060247261A1

  公开（公告）日：2006-11-02

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物，包含这些化合物的药物组合物以及它们在治疗疾病，特别是由于大麻素受体活性的增加或减少而直接或间接引起疾病，尤其是疼痛方面的应用。
• Pyrimidine derivatives as CB2 cannabinoid receptor modulators
  申请人：GLAXO GROUP LIMITED

  公开号：EP1736470A2

  公开（公告）日：2006-12-27

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物及其在治疗疾病（尤其是疼痛）中的用途，这些疾病是由大麻素受体活性的增加或降低直接或间接引起的。